SELLAS Life Sciences Group (SLS) Liabilities and Shareholders Equity: 2011-2024
Historic Liabilities and Shareholders Equity for SELLAS Life Sciences Group (SLS) over the last 9 years, with Sep 2024 value amounting to $26.5 million.
- SELLAS Life Sciences Group's Liabilities and Shareholders Equity rose 227.79% to $26.5 million in Q3 2024 from the same period last year, while for Sep 2024 it was $72.3 million, marking a year-over-year decrease of 5.77%. This contributed to the annual value of $6.2 million for FY2023, which is 70.31% down from last year.
- As of Q3 2024, SELLAS Life Sciences Group's Liabilities and Shareholders Equity stood at $26.5 million, which was up 75.31% from $15.1 million recorded in Q2 2024.
- SELLAS Life Sciences Group's Liabilities and Shareholders Equity's 5-year high stood at $46.0 million during Q4 2020, with a 5-year trough of $6.2 million in Q4 2023.
- In the last 3 years, SELLAS Life Sciences Group's Liabilities and Shareholders Equity had a median value of $21.4 million in 2022 and averaged $20.8 million.
- As far as peak fluctuations go, SELLAS Life Sciences Group's Liabilities and Shareholders Equity plummeted by 70.31% in 2023, and later surged by 227.79% in 2024.
- Over the past 5 years, SELLAS Life Sciences Group's Liabilities and Shareholders Equity (Quarterly) stood at $46.0 million in 2020, then crashed by 42.94% to $26.3 million in 2021, then decreased by 20.29% to $20.9 million in 2022, then tumbled by 70.31% to $6.2 million in 2023, then soared by 227.79% to $26.5 million in 2024.
- Its Liabilities and Shareholders Equity stands at $26.5 million for Q3 2024, versus $15.1 million for Q2 2024 and $24.4 million for Q1 2024.